Maculopapular eruption, pruritus, and SJS/TEN are more commonly seen with anti-CTLA-4 blockades, whereas lichenoid dermatitis, psoriasiform dermatitis, vitiligo-like depigmentation, and bullous pemphigoid more frequently occur in patients treated with anti-PD-1/PD-L1 blockades. This evidence concerns the gene CTLA4 and bullous pemphigoid.